Dr. Christine Sturchler, Prof. Peter Mol, Caroline Vass, Dr. Hannah Penton, Dr. Marco Boeri, Teodora Trasieva.
The following topics were presented during day 1 of the patient-focused drug development meeting:
“The perspective of Patients as Research Partners in Patient Preference Studies”, presented by Dr. Christine Sturchler, Director of Patient Engagement Scientific Excellence at Novartis
“The perspective of an EU regulator”, presented by prof. Petr Mol, CHMP member for the Dutch Medicines Evaluation Board and professor of drug regulatory science at the University Medical Center Groningen
“Incorporating Patient outcomes, Preferences, and Perspectives into HTA”, presented by Caroline Vass, Senior Economist in the Health Preference Assessment team at RTI Health Solutions; Dr. Hannah Penton, a Senior Scientist in the Patient-Centered Outcomes team at OPEN health; and Dr. Marco Boeri, Director of Preference Research at OPEN Health and honorary professor in practice in Health Economics at Queen’s University Belfast